Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 153M | 8.6% |
| Gross Profit | 104M | 12.2% |
| Cost of Revenue | 49M | 1.6% |
| Operating expense | 146M | 5.5% |
| Net Income | -38M | 36.8% |
| EBITDA | -40M | 28.3% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 930M | 0.7% |
| Total Liabilities | 206M | 0.8% |
| Total Equity | 724M | 0.7% |
| Shares Outstanding | 120M | 0.6% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 7.5M | 147.7% |
| Cash from investing | 12M | 12.4% |
| Cash from financing | 4.6M | 181% |
EPS
Financial Highlights for 10X Genomics in Q2 '24
10X Genomics reported a revenue of 153M, which is a 8.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 104M, marking a 12.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 49M, a 1.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 146M, showing a -5.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -38M, showing a 36.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -40M, showing a 28.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for 10X Genomics with growth in revenue, gross profit, and net income.
